Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
37.72
-1.34 (-3.43%)
At close: Mar 3, 2026, 4:00 PM EST
38.20
+0.48 (1.27%)
After-hours: Mar 3, 2026, 7:18 PM EST
Soleno Therapeutics Employees
Soleno Therapeutics had 152 employees as of September 30, 2025. The number of employees increased by 60 or 65.22% compared to the same quarter last year.
Employees
152
Change
60
Growth
65.22%
Revenue / Employee
$1,252,664
Profits / Employee
$134,704
Market Cap
1.95B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 152 | 60 | 65.22% |
| Jun 30, 2025 | 133 | - | - |
| Mar 31, 2025 | 115 | 82 | 248.48% |
| Dec 31, 2024 | 92 | 59 | 178.79% |
| Dec 31, 2023 | 33 | 8 | 32.00% |
| Dec 31, 2022 | 25 | 5 | 25.00% |
| Dec 31, 2021 | 20 | 3 | 17.65% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,869 |
| Ultragenyx Pharmaceutical | 1,371 |
| Recursion Pharmaceuticals | 800 |
| Ascentage Pharma Group International | 605 |
| Nuvation Bio | 291 |
| Syndax Pharmaceuticals | 270 |
| Celldex Therapeutics | 186 |
| Aurinia Pharmaceuticals | 130 |
SLNO News
- 5 days ago - Soleno Therapeutics, Inc. (SLNO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR - GlobeNewsWire
- 2 months ago - Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism - GlobeNewsWire
- 2 months ago - Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses - PRNewsWire
- 3 months ago - Soleno Therapeutics Announces the Passing of Board Member William G. Harris - GlobeNewsWire
- 3 months ago - Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% – Hagens Berman - GlobeNewsWire
- 3 months ago - Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm - GlobeNewsWire
- 4 months ago - Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement - GlobeNewsWire